Affinity of WY 26703 for central and peripheral alpha 1- and alpha 2-adrenoreceptors in the rat; comparison with yohimbine. 1984

C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten

The antagonist activity of Wy 26703 at vascular postjunctional alpha-adrenoreceptors was quantified against the methoxamine and B-HT 920-induced increase in diastolic pressure in pithed rats. For Wy 26703 pA2-values (= -log dose antagonist evoking a 2-fold shift for the agonist dose-response curve) of 4.96 and 6.43 are found, respectively, whereas for yohimbine values of 5.72 and 6.83 have been reported. The blocking potencies of Wy 26703 and yohimbine have been compared at cardiac prejunctional alpha 2- adrenoreceptors in rats. pA2-values of 6.84 and 6.97, respectively, resulted for the antagonism against the B-HT 920-induced inhibition of stimulation-induced tachycardia. At central alpha-binding sites Wy 26703 and yohimbine were compared for their ability to displace [3H]-prazosin, [3H]-yohimbine and [3H]-clonidine from their specific binding sites in rat brain homogenates. For both compounds binding data indicated a preferential affinity for cental alpha 2- over central alpha 1-binding sites. Wy 26703 exhibited a greater selectivity for cental alpha 2- as compared with central alpha 2-sites than did yohimbine. It is concluded that Wy 26703 behaves as a potent alpha 2-adrenoreceptor blocking agent, that is more selective than yohimbine for postjunctional and central alpha 2-adrenoreceptors as compared with alpha 1-adrenoreceptors. At cardiac prejunctional alpha 2-adrenoreceptors both blocking drugs appeared to be equipotent.

UI MeSH Term Description Entries
D008297 Male Males
D008729 Methoxamine An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION. Methoxamedrin,Methoxamine Hydrochloride,Metoxamine Wellcome,Vasoxin,Vasoxine,Vasoxyl,Vasylox,Hydrochloride, Methoxamine,Wellcome, Metoxamine
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011807 Quinolizines
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003000 Clonidine An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. Catapres,Catapresan,Catapressan,Chlophazolin,Clofelin,Clofenil,Clonidine Dihydrochloride,Clonidine Hydrochloride,Clonidine Monohydrobromide,Clonidine Monohydrochloride,Clopheline,Dixarit,Gemiton,Hemiton,Isoglaucon,Klofelin,Klofenil,M-5041T,ST-155,Dihydrochloride, Clonidine,Hydrochloride, Clonidine,M 5041T,M5041T,Monohydrobromide, Clonidine,Monohydrochloride, Clonidine,ST 155,ST155

Related Publications

C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
January 2001, Archiv der Pharmazie,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
January 1981, Thrombosis research,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
January 1988, Farmakologiia i toksikologiia,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
March 1982, Naunyn-Schmiedeberg's archives of pharmacology,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
April 1981, European journal of pharmacology,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
December 1981, Journal of autonomic pharmacology,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
January 1984, Journal of cardiovascular pharmacology,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
March 1986, Journal of autonomic pharmacology,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
January 1981, Naunyn-Schmiedeberg's archives of pharmacology,
C Korstanje, and H N Doods, and A De Jonge, and M J Thoolen, and B Wilffert, and P B Timmermans, and P A Van Zwieten
February 1989, Journal of autonomic pharmacology,
Copied contents to your clipboard!